- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Artelo Biosciences reported positive results suggesting potential for FDA approval.
3 reports, 1 independent
Updated Sep 3
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Artelo Biosciences reported positive results suggesting potential for FDA approval.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Artelo Biosciences reported positive results suggesting potential for FDA approval.1 source
- ART12.11 showed promising antidepressant effects.
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- Research advances have led to the approval of new therapies by the FDA.
- FDA communicated eligibility for accelerated approval for ProKidney Corp., which plans to present study results at ASN.
- FDA approved a drug based on UVA research led by Xuemei Huang.
- FDA approval expands patient access to therapies for ACCORD.
- Vera Therapeutics and the FDA agreed to shift the assessment of a clinical study.
Coverage
Newest first; wire copies grouped- GlobeNewswireArtelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (N
- GlobeNewswireArtelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain Safety and Pharmacokinetic Data Support Dosin
- Unknown outlet